Related Experiment Videos
Platelet-derived growth factor (PDGF)-signaling mediates radiation-induced apoptosis in human prostate cancer cells
1Department of Radiation Oncology, Wayne State University School of Medicine, Detroit, MI 48202, USA.
Abstract:
Platelet-derived growth factor (PDGF) signals a diversity of cellular responses in vitro, including cell proliferation, survival, transformation, and chemotaxis. PDGF functions as a "competence factor" to induce a set of early response genes expressed in G1 including p21WAF1/CIP1, a functional mediator of the tumor suppressor gene p53 in G1/S checkpoint. For PDGF-stimulated cells to progress beyond G1 and transit the cell cycle completely, progression factors in serum such as insulin and IGF-1 are required. We have recently shown a novel role of PDGF in inducing apoptosis in growth-arrested murine fibroblasts. The PDGF-induced apoptosis is rescued by insulin, suggesting that G1/S checkpoint is a critical determinant for PDGF-induced apoptosis. Because recent studies suggest that radiation-induced signal transduction pathways interact with growth factor-mediated signaling pathways, we have investigated whether activation of the PDGF-signaling facilitates the radiation-induced apoptosis in the absence of functional p53. For this study we have used the 125-IL cell line, a mutant p53-containing, highly metastatic, and hormone-unresponsive human prostate carcinoma cell line. PDGF signaling is constitutively activated by transfection with a p28v-sis expression vector, which was previously shown to activate PDGF alpha- and beta- receptors. Although the basal level of p21WAF1/CIP1 expression and radiation-induced apoptosis were not detectable in control 125-IL cells as would be predicted in mutant p53-containing cells, activation of PDGF-signaling induced expression of p21WAF1/CIP1 and radiation-induced apoptosis. Our study suggests that the level of "competence" growth factors including PDGF may be one of the critical determinants for radiation-induced apoptosis, especially in cells with loss of p53 function at the site of radiotherapy in vivo.
Insights
Platelet-derived growth factor (PDGF) activates p21WAF1/CIP1 expression and radiation-induced apoptosis in human prostate cancer cells lacking functional p53. This suggests PDGF levels are critical for radiotherapy outcomes in p53-deficient tumors.
Area of Science:
- Cell Biology
- Cancer Research
- Molecular Oncology
Background:
- Platelet-derived growth factor (PDGF) regulates cellular processes like proliferation and survival.
- PDGF acts as a competence factor, inducing early response genes such as p21WAF1/CIP1, a mediator of the p53 tumor suppressor in the G1/S checkpoint.
- Insulin and IGF-1 are required for cell cycle progression beyond G1, and insulin rescues PDGF-induced apoptosis, highlighting the G1/S checkpoint's role.
Purpose of the Study:
- To investigate if PDGF signaling activation facilitates radiation-induced apoptosis in cells lacking functional p53.
- To explore the interaction between growth factor signaling and radiation-induced pathways in cancer cells.
Main Methods:
- Utilized the 125-IL human prostate carcinoma cell line, characterized by mutant p53, high metastatic potential, and hormone unresponsiveness.
- Constitutively activated PDGF signaling by transfecting with a p28v-sis expression vector, known to activate PDGF alpha- and beta- receptors.
- Assessed p21WAF1/CIP1 expression and radiation-induced apoptosis in control and PDGF-activated cells.
Main Results:
- Control 125-IL cells, with mutant p53, showed no detectable basal p21WAF1/CIP1 expression or radiation-induced apoptosis.
- Activation of PDGF signaling in 125-IL cells led to induced expression of p21WAF1/CIP1.
- PDGF signaling activation also resulted in detectable radiation-induced apoptosis in these cells.
Conclusions:
- PDGF signaling can induce p21WAF1/CIP1 expression and facilitate radiation-induced apoptosis in human prostate cancer cells with non-functional p53.
- The level of competence growth factors, such as PDGF, may be a critical determinant for the efficacy of radiation therapy, particularly in tumors with p53 loss of function.